PETER ARDUINI NAMED CEO OF GE HEALTHCARE

BOSTON – June 24, 2021– Today GE (NYSE: GE) announced the appointment of Peter Arduini as president and Chief Executive Officer of GE Healthcare effective January 3, 2022. Arduini will succeed Kieran Murphy who will continue to serve in his current role until the end of 2021 and then he will serve as a strategic... Read more

PerkinElmer Provides Update on Second Quarter Performance and Schedules Earnings Call for Wednesday, July 28, 2021

Company anticipates 2Q21 revenue and earnings to be above previously communicated guidance WALTHAM, Mass.–(BUSINESS WIRE)–Jun. 24, 2021– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced ahead of this morning’s Virtual Investor and Analyst Day that it anticipates exceeding its previously announced financial guidance for the second quarter... Read more

GE Healthcare and Wayra select six AI-led healthtech start-ups for EMEA Edison™ Accelerator

The ‘Edison Accelerator’ provides world-class clinical, technical and commercial mentorship to EMEA-based start-ups London, UK – 24 June 2021 – Six healthtech start-ups have officially become the first cohort of the Edison Accelerator in EMEA – a healthcare start-up and scale-up acceleration programme designed by GE Healthcare in partnership with innovation organisation Wayra UK. The... Read more

GE Healthcare and Wayra select five AI-led healthtech start-ups for first Edison™ Accelerator

The ‘Edison Accelerator’ provides world-class clinical, technical and commercial mentorship to EMEA-based start-ups London, UK – 24 June 2021 – Five healthtech start-ups have officially become the first cohort of the Edison Accelerator in EMEA – a healthcare start-up and scale-up acceleration programme designed by GE Healthcare in partnership with innovation organisation Wayra UK. The... Read more

FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)

If approved, PDS would be the first and only eye implant with continuous drug delivery that offers people living with nAMD an alternative to frequent eye injections A pivotal study showed PDS extends time between treatments up to six months for more than 98% of patients and provides vision outcomes equivalent to monthly ranibizumab injections... Read more

Pacific Biosciences and Rady Children’s Institute for Genomic Medicine Announce its First Research Collaboration for Whole Genome Sequencing

MENLO PARK, Calif., June 23, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Rady Children’s Institute for Genomic Medicine (RCIGM), a mission-driven, non-profit seeking to save lives and improve outcomes for patients, clinicians and families, shared today that they are... Read more

Tecan expands its commercial reach, its capabilities and its US and Asia presence with the acquisition of Paramit Corporation

Tecan to acquire Paramit Corporation, a leading OEM developer and manufacturer of medical devices and life sciences instruments, for a total consideration of USD 1.0 billion (CHF 920 million)  In full year 2021, Paramit is expected to generate around USD 280m in sales (CHF 257m) and around USD 50m EBITDA (CHF 46m), before acquisition-related costs  Transaction expected to be immediately and significantly accretive to earnings per share (EPS) upon closing  Adds complementary expertise, broadens design, development and manufacturing capabilities Expansion into the attractive and fast-growing medical... Read more

Agilent Completes the InfinityLab Bio LC Portfolio

Launching the full range for biopharma analysis at the Agilent InfinityLab LC Virtual Conference SANTA CLARA, Calif., June 22, 2021  Agilent Technologies Inc. (NYSE: A) today announced the launch of three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release is central to the Agilent portfolio of complete Bio LC solutions,... Read more